Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

por Hamberg, Paul, Woo, Margaret M., Chen, Lin-Chi, Verweij, Jaap, Porro, Maria Grazia, Zhao, Lily, Li, Wenkui, van der Biessen, Diane, Sharma, Sunil, Hengelage, Thomas, de Jonge, Maja
Publicado 2011

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

por Azaro, Analía, Rodón, Jordi, Machiels, Jean-Pascal, Rottey, Sylvie, Damian, Silvia, Baird, Richard, Garcia-Corbacho, Javier, Mathijssen, Ron H. J., Clot, Pierre-François, Wack, Claudine, Shen, Liji, de Jonge, Maja J. A.
Publicado 2016

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

por de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric
Publicado 2018

Core values of patients with advanced cancer considering participation in an early-phase clinical trial: a qualitative study

por van Gurp, Jelle L. P., van Lent, Liza G. G., Stoel, Nicole, van der Rijt, Carin C. D., de Jonge, Maja J. A., Pulleman, Saskia M., van Weert, Julia C. M., Hasselaar, Jeroen
Publicado 2022

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

por Steeghs, Neeltje, Mathijssen, Ron H. J., Wessels, Judith A. M., de Graan, Anne-Joy, van der Straaten, Tahar, Mariani, Mariangela, Laffranchi, Bernard, Comis, Silvia, de Jonge, Maja J. A., Gelderblom, Hans, Guchelaar, Henk-Jan
Publicado 2010

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

por Jung, Joonil, Lee, Joon Sang, Dickson, Mark A., Schwartz, Gary K., Le Cesne, Axel, Varga, Andrea, Bahleda, Rastilav, Wagner, Andrew J., Choy, Edwin, de Jonge, Maja J., Light, Madelyn, Rowley, Steve, Macé, Sandrine, Watters, James
Publicado 2016

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

por Kreitman, Robert J., Moreau, Philippe, Ravandi, Farhad, Hutchings, Martin, Gazzah, Anas, Michallet, Anne-Sophie, Wainberg, Zev A., Stein, Alexander, Dietrich, Sascha, de Jonge, Maja J. A., Willenbacher, Wolfgang, De Grève, Jacques, Arons, Evgeny, Ilankumaran, Palanichamy, Burgess, Paul, Gasal, Eduard, Subbiah, Vivek
Publicado 2023

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

por Verheijen, Remy B., van der Biessen, Diane A. J., Hotte, Sebastien J., Siu, Lillian L., Spreafico, Anna, de Jonge, Maja J. A., Pronk, Linda C., De Vos, Filip Y. F. L., Schnell, David, Hirte, Hal W., Steeghs, Neeltje, Lolkema, Martijn P.
Publicado 2019

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

por van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.
Publicado 2020

Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing

por van Lent, Liza G. G., de Jonge, Maja J. A., van der Ham, Mirte, van Mil, Marjolein, Gort, Eelke H., Hasselaar, Jeroen, Oomen-de Hoop, Esther, van der Rijt, Carin C. D., van Weert, Julia C. M., Lolkema, Martijn P.
Publicado 2022

Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT)

por van Lent, Liza G. G., Stoel, Nicole K., van Weert, Julia C. M., van Gurp, Jelle, de Jonge, Maja J. A., Lolkema, Martijn P., Gort, Eelke H., Pulleman, Saskia M., Oomen-de Hoop, Esther, Hasselaar, Jeroen, van der Rijt, Carin C. D.
Publicado 2019

Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data

por Derks, Sophie H. A. E., Jongen, Joost L. M., van der Meer, Edgar L., Ho, Li Shen, Slagter, Cleo, Joosse, Arjen, de Jonge, Maja J. A., Schouten, Joost W., Oomen-de Hoop, Esther, van den Bent, Martin J., van der Veldt, Astrid A. M.
Publicado 2023

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

por de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Publicado 2019

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

por LoRusso, Patricia, Ratain, Mark J., Doi, Toshihiko, Rasco, Drew W., de Jonge, Maja J. A., Moreno, Victor, Carneiro, Benedito A., Devriese, Lot A., Petrich, Adam, Modi, Dimple, Morgan-Lappe, Susan, Nuthalapati, Silpa, Motwani, Monica, Dunbar, Martin, Glasgow, Jaimee, Medeiros, Bruno C., Calvo, Emiliano
Publicado 2022

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

por Virtakoivu, Reetta, Rannikko, Jenna H., Viitala, Miro, Vaura, Felix, Takeda, Akira, Lönnberg, Tapio, Koivunen, Jussi, Jaakkola, Panu, Pasanen, Annika, Shetty, Shishir, de Jonge, Maja J.A., Robbrecht, Debbie, Ma, Yuk Ting, Skyttä, Tanja, Minchom, Anna, Jalkanen, Sirpa, Karvonen, Matti K., Mandelin, Jami, Bono, Petri, Hollmén, Maija
Publicado 2021

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

por van der Biessen, Diane A. J., Gietema, Jourik A., de Jonge, Maja J. A., Desar, Ingrid M. E., den Hollander, Martha W., Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K., Timms, Kirsten M., Ansell, Peter, Ratajczak, Christine K., Shepherd, Stacie Peacock, van Herpen, Carla M. L.
Publicado 2018

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded...

por de Leng, Wendy W. J., Gadellaa-van Hooijdonk, Christa G., Barendregt-Smouter, Françoise A. S., Koudijs, Marco J., Nijman, Ies, Hinrichs, John W. J., Cuppen, Edwin, van Lieshout, Stef, Loberg, Robert D., de Jonge, Maja, Voest, Emile E., de Weger, Roel A., Steeghs, Neeltje, Langenberg, Marlies H. G., Sleijfer, Stefan, Willems, Stefan M., Lolkema, Martijn P.
Publicado 2016

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

por Vieito, Maria, Simonelli, Matteo, de Vos, Filip, Moreno, Victor, Geurts, Marjolein, Lorenzi, Elena, Macchini, Marina, van den Bent, Martin J, Del Conte, Gianluca, de Jonge, Maja, Martín-Soberón, Maria Cruz, Amoroso, Barbara, Sanchez-Perez, Tania, Zuraek, Marlene, Hanna, Bishoy, Aronchik, Ida, Filvaroff, Ellen, Chang, Henry, Mendez, Cristina, Arias Parro, Marina, Wei, Xin, Nikolova, Zariana, Sepulveda, Juan Manuel
Publicado 2022

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

por Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Gazzah, Anas, Lassen, Ulrik, Stein, Alexander, Wen, Patrick Y., Dietrich, Sascha, de Jonge, Maja J. A., Blay, Jean-Yves, Italiano, Antoine, Yonemori, Kan, Cho, Daniel C., de Vos, Filip Y. F. L., Moreau, Philippe, Fernandez, Elena Elez, Schellens, Jan H. M., Zielinski, Christoph C., Redhu, Suman, Boran, Aislyn, Passos, Vanessa Q., Ilankumaran, Palanichamy, Bang, Yung-Jue
Publicado 2023

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

por Weeber, Fleur, Cirkel, Geert A., Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G.M., Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M., van Stralen, Marijn, Veldhuis, Wouter B., Besselink, Nicolle J.M., Horlings, Hugo M., Steeghs, Neeltje, de Jonge, Maja J., Langenberg, Marlies H.G., Wessels, Lodewyk F.A., Cuppen, Edwin P.J.G., Schellens, J.H., Sleijfer, Stefan, Lolkema, Martijn P., Voest, Emile E.
Publicado 2017